How has been the historical performance of Parmax Pharma?

Answer:The historical performance of Parmax Pharma shows significant fluctuations in its financial metrics over the years. Breakdown: Parmax Pharma's net sales have seen a notable increase from INR 11.05 crore in March 2024 to INR 28.20 crore in March 2025, following a decline from INR 15.42 crore in March 2023 and INR 18.25 crore in March 2022. The total operating income mirrored this trend, rising to INR 28.20 crore in March 2025 from INR 11.05 crore in March 2024. However, the company's total expenditure also increased, reaching INR 27.95 crore in March 2025, up from INR 14.43 crore in March 2024. This led to an operating profit of INR 0.25 crore in March 2025, a recovery from a loss of INR 3.38 crore in March 2024. Despite this, the profit before tax remained negative at INR -2.40 crore in March 2025, although it improved from INR -5.66 crore in March 2024. The profit after tax also showed a loss of INR -2.09 crore in March 2025, compared to INR -5.75 crore in March 2024. The company's reserves turned negative, standing at INR -6.44 crore in March 2025, down from INR -4.35 crore in March 2024. Total liabilities increased to INR 18.56 crore in March 2025 from INR 15.33 crore in March 2024, while total assets rose to INR 18.56 crore in March 2025 from INR 15.33 crore in March 2024. The cash flow from operating activities was stagnant at INR 0.00 crore in March 2024 and March 2023, indicating challenges in generating cash from operations. Overall, while Parmax Pharma showed growth in sales and operating income, it continues to face significant challenges in profitability and maintaining positive reserves.